HF-158K1 by HighField Biopharmaceuticals for Pancreatic Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.

A French startup wants to decentralize cell and gene therapy manufacturing, making it ‘the size of a book’

Jérémie Laurent stumbled into biology. While studying aerospace engineering, all of Laurent’s classes were about math, so he began taking biology classes as an escape.

June 28, 2023

What happened when my mother became the first 2024 West Nile patient in Manhattan

What was that mosquito thinking as the six needles of its proboscis mouth bit into my mother’s skin? Had it taken a long, unplanned journey

September 24, 2024

What happens to health programs if the federal government shuts down?

For the first time since 2019, congressional gridlock is poised to at least temporarily shut down big parts of the federal government — including many

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.